• Cumberland Pharmaceuticals disclosed Phase 2a trial results for ifetroban in high-risk solid tumors, with findings already presented in the announcement.
• The study met its primary goal on safety, supporting continued development of the drug as a potential metastasis-prevention therapy.
• Secondary readouts showed fewer metastatic recurrences in the ifetroban group, with a signal for fewer metastasis-related deaths versus placebo.
• Management framed the data as a basis for larger, later-stage studies intended to confirm clinical benefit and expand the safety database.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606020905PR_NEWS_USPR_____CL73324) on June 02, 2026, and is solely responsible for the information contained therein.